Clinuvel Pharmaceuticals : Appendix 4C - quarterly

C O M P A N Y A N N O U N C E M E N T

Appendix 4C and Activity Report

CLINUVEL REPORTS HIGHEST ANNUAL ROLLING CASH RECEIPTS

ASX:	CUV
XETRA-DAX:	UR9
NASDAQ INTERNATIONAL	CLVLY
DESIGNATION:

CLINUVEL PHARMACEUTICALS LTD today announced	KEY CASH FLOW HIGHLIGHTS Q2 FY21:
its Appendix 4C - Quarterly Cashflow Report and
Activity Report for the period 01 October to 31
December 2020. All figures are rounded and reported in
Australian dollars.

OPERATING CONDITIONS AND THE GLOBAL ECONOMY

COMMENTARY

Graph 1: Annual Cash Receipts and

Operating Expenditures

(A$m, on rolling quarterly basis)

	Cash Receipts		Operating Payments

35.0
30.0
25.0
20.0
15.0
10.0
5.0
0.0
Jun-17	Jun-18	Jun-19	Jun-20

"The continued performance of the Group stems from our measured strategy, consistent execution, and treatment demand from both the USA and Europe, which have contributed to a new high in annual cash receipts," CLINUVEL's Chief Financial Officer, Mr Darren Keamy said.

"Against the ongoing backdrop of economic uncertainty, and in a quarter where cash receipts are historically lower, reflecting the seasonal demand, we have now been able to deliver a positive net cash result in the December quarter, the first since 2017.

C O M P A N Y A N N O U N C E M E N T

"As of today, CLINUVEL is in a good position to pursue further investments in its R&D and clinical programs, aiming to deliver long-term value while building out the CLINUVEL Group of companies," Mr Keamy said.

STRONG CASH RECEIPTS AND NET CASH

ANNUAL TREND IN CASH RECEIPTS AND EXPENDITURES

CONTROLLED GROWTH IN EXPENDITURES

REVIEW OF KEY ACTIVITIES

•

•

•

C O M P A N Y A N N O U N C E M E N T

•

About CLINUVEL PHARMACEUTICALS LIMITED

Head of Investor Relations

Investor Enquiries

Forward-Looking Statements

C O M P A N Y A N N O U N C E M E N T